Genetic Diagnosis and Management of Connective Tissue Disorders Related to Aneurysms
Introduction to Genetic Testing
- The American College of Medical Genetics recommends comprehensive gene panel testing for FBN1, TGFBR1, TGFBR2, COL3A1, ACTA2, and MYH11, rather than single-gene testing, to diagnose connective tissue disorders related to aneurysms 1, 2, 4
- Current FBN1 testing detects mutations in 90-95% of unequivocal Marfan syndrome patients, highlighting the importance of comprehensive testing 3
Essential Concurrent Diagnostic Evaluation
- The American Heart Association recommends transthoracic echocardiography (TTE) measuring aortic annulus, sinuses of Valsalva, sinotubular junction, and ascending aorta with Z-score calculation for patients with suspected connective tissue disorders related to aneurysms 5, 6, 3
- If TTE inadequately visualizes the aortic root or ascending aorta, the European Society of Cardiology recommends obtaining CT or MRI of the thoracic aorta 5, 6
- For suspected Loeys-Dietz syndrome, magnetic resonance angiography of the head, neck, thorax, abdomen, and pelvis is mandatory due to diffuse arterial tortuosity 1
Critical Clinical Context for Morbidity and Mortality
- Genetic testing has implications beyond diagnosis that directly impact survival, including risk stratification and family cascade testing 3, 4
- The American College of Cardiology recommends beta-blocker therapy for aortic root dilation in all confirmed cases of connective tissue disorders related to aneurysms 1, 2, 4
Management Implications
- Prophylactic surgical repair thresholds vary by genetic diagnosis, with the American Heart Association recommending 5.0-5.5 cm for Marfan syndrome (FBN1) 1, 6, 4.5 cm or smaller for Loeys-Dietz syndrome (TGFBR1/2) 1, 4, and 4.5-5.0 cm for ACTA2, MYH11, SMAD3 mutations 1, 2
- All first-degree relatives of affected individuals should undergo aortic imaging regardless of genetic testing results, as recommended by the American College of Medical Genetics 4, 7